NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,607 | -97.2% | 21,167 | -97.3% | 0.00% | – |
| Q2 2023 | $449,655 | +22.6% | 781,736 | +49.8% | 0.00% | – |
| Q1 2023 | $366,708 | +6.7% | 521,707 | +242.9% | 0.00% | – |
| Q4 2022 | $343,814 | +473.0% | 152,130 | +701.8% | 0.00% | – |
| Q3 2022 | $60,000 | -56.2% | 18,974 | -47.4% | 0.00% | – |
| Q2 2022 | $137,000 | -98.5% | 36,054 | -97.8% | 0.00% | -100.0% |
| Q1 2022 | $8,979,000 | -10.7% | 1,665,853 | +123.8% | 0.00% | 0.0% |
| Q4 2021 | $10,058,000 | +45.4% | 744,484 | +93.3% | 0.00% | +50.0% |
| Q3 2021 | $6,916,000 | +25.5% | 385,117 | +19.9% | 0.00% | +100.0% |
| Q2 2021 | $5,512,000 | +399.7% | 321,195 | +482.5% | 0.00% | – |
| Q1 2021 | $1,103,000 | -53.3% | 55,144 | -60.3% | 0.00% | – |
| Q4 2020 | $2,362,000 | +7.8% | 138,931 | +5.1% | 0.00% | -100.0% |
| Q3 2020 | $2,192,000 | -39.4% | 132,142 | -15.4% | 0.00% | -66.7% |
| Q2 2020 | $3,619,000 | +340.3% | 156,266 | +239.1% | 0.00% | – |
| Q1 2020 | $822,000 | -43.2% | 46,089 | -31.2% | 0.00% | -100.0% |
| Q4 2019 | $1,447,000 | +57.8% | 67,012 | +33.1% | 0.00% | 0.0% |
| Q3 2019 | $917,000 | +290.2% | 50,362 | +661.3% | 0.00% | – |
| Q2 2019 | $235,000 | -42.5% | 6,615 | -45.7% | 0.00% | -100.0% |
| Q1 2019 | $409,000 | -68.3% | 12,185 | -68.9% | 0.00% | -66.7% |
| Q4 2018 | $1,289,000 | -49.6% | 39,201 | -6.6% | 0.00% | -40.0% |
| Q3 2018 | $2,558,000 | -87.6% | 41,966 | -90.0% | 0.01% | -89.8% |
| Q2 2018 | $20,564,000 | +1006.2% | 421,149 | +2306.6% | 0.05% | +880.0% |
| Q1 2018 | $1,859,000 | -32.7% | 17,500 | -62.2% | 0.01% | -37.5% |
| Q4 2017 | $2,761,000 | +255.3% | 46,241 | +39.7% | 0.01% | +166.7% |
| Q1 2017 | $777,000 | +344.0% | 33,106 | +218.3% | 0.00% | +200.0% |
| Q4 2015 | $175,000 | +36.7% | 10,400 | +2.0% | 0.00% | 0.0% |
| Q2 2015 | $128,000 | -52.4% | 10,200 | -54.2% | 0.00% | -66.7% |
| Q3 2014 | $269,000 | – | 22,284 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |